Literature DB >> 12556656

Meta-analysis, meta-regression, and meta-physics.

John B Kostis1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556656      PMCID: PMC8099214          DOI: 10.1111/j.1524-6175.2003.01487.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  13 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 2.  Is it time for a new approach to the initial treatment of hypertension?

Authors:  M Moser
Journal:  Arch Intern Med       Date:  2001-05-14

3.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

Authors:  R O Estacio; B W Jeffers; W R Hiatt; S L Biggerstaff; N Gifford; R W Schrier
Journal:  N Engl J Med       Date:  1998-03-05       Impact factor: 91.245

4.  Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

Authors:  P Tatti; M Pahor; R P Byington; P Di Mauro; R Guarisco; G Strollo; F Strollo
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

5.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.

Authors:  M Pahor; B M Psaty; M H Alderman; W B Applegate; J D Williamson; C Cavazzini; C D Furberg
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

6.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.

Authors:  J B Kostis
Journal:  Am J Hypertens       Date:  1995-09       Impact factor: 2.689

9.  Roundtable Discussion: Blood pressure lowering by any means, or do specific medications make a difference?

Authors:  M Moser; T G Pickering; M A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Nov-Dec       Impact factor: 3.738

10.  Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials.

Authors:  Ji-Guang Wang; Jan A Staessen
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jan-Feb       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.